Upload
phungtruc
View
219
Download
5
Embed Size (px)
Citation preview
� � ����������Vol. 32, pp. 461�469, 2004
������� C��� ����������������������� !
���
��
���
��1 �
�
�
�
��
��
��1 �
�
��
���
��1 �
��
���
��
��
��1
���
��
���
��1 �
�
����
����
2 ��
��
���
��2 �
�
�
�!�
�"2
��� : � 16� 10 19��
� �!�"#$%&���'��()* C+�,-./01�2�3�4�5�67'8�9:��;�<�'��=*# 2001� 6 >?��=*�<�' 2001� 12 1!�"#$%&���@A������1��BCD�=$ 52�'EFG=H8�'IJ*# �2�KLM�C�N?)$ OPQC !�"R�86���S#�86���TU)�80��;VJ*# �2�1$%K&'W1(XYZ;1)[\]^_$ �<�1��C\]$ �2�1&�$%'\]`aC*b9:cGde+;V:Gfg?)*# �4�5�67dhij)HP:/0KLk13,1 1'lNHP*# �2�C\:m�nS�K�N?)o$ �<�'��=$ pNq>ir�'IscGd$ m�'tLCuv9:w;-�Gxj)*#
����C+�,-.$ �2�$ !�"#$%&�$ �@A��$ �<�
C+-.yz{|}~��K��L�C 200.�P:G�/()H�]1�$ 0�=H�_G$ 1�� � 30�1��;-�23-�C�I9: 2�# =*dJH$ yz{|'3�=$ -�23-��1�I'GN:cGd�4;V:# !�"#$%&��IFN� Kc1��C5�()$ yz{|3�1�i?o-&�$ (?CK�67�'D�9:cGd�8()HP:3�5�# (?C$ 2001� 12 \]9�:�GiJ*�@A��G1������������K$ ��;m��;G()Hp*�<�+ 1b >�^yz{|=1M�CE=H�^P��>' 9cGd�8()HP:6$7�# =>=¡1?@$ ¢%1�
2�d£�9:*N8$9�$ m�'¤A9:�;1/01¥BKpP#!�"#$%&�m�KO_1�2�'Cs*
N$ ¦?)*<�B§D;�2�'`aC*b9:cGK;=PGfg?):# c1*N$ �<�'�PHM¨1£�$%'E©:cGd-�;V:Gfg?):# c)�;ª«M¨C¬=HK Self-ratingDepression Scale �SDS�, Hospital Anxiety and De-pression Scale �HAD %� i®1�<�'�P*)[d�D¯>?()HP:10$11�# �*$ /01Quality of LifeC¬=HK SF36�<�311$12�Hepa-
titis Quality of Life Questionnaire �HQLQ� '�P*8�13$14�d°¯>?)[()HP:# =>=id?±kM¨'F²�C³g*�<�'!�"#$%&�m�´C��=*)[Kµ%1E©G*¦]¶?)iP#��������·¸¹�-ºD�¯H;
1 �������� »¼I2 J D��·¸¹�-ºD��
461
45
�� 2001� 6���� IFN ��������� ���� ������������������ � ������ !��"#$��%&�'��(���)����*+�,-.)� /�� � 12��������0�� 1�(���2�� ����*+�%&�.)� 345�67�89� ��� !:�!;<=>�,#?@9�(���AB�C��)�9� D�EF�55��GH��
�����
� ������ ���������2001� 6���2�)�(� �Figure 1� �� IFN ����I,8� 6�����(�,-)� �(��J��� K��(L�MNLO�� �J��P�� D�0QRST�(��C��)� �(��JU�#����JUT �D�V� ���W-)XYPZ[��\'�)� �(��(]L�^S��/_� ���`a^S���JUT�b/_)�� ����������������������2001 � 12 ���� 1)��2�)�(� �Fig-ure � ��� ����I,8� 52 �����(�,-)� �(��J���(��#����c�d� �(������ ����' ��,-)�� ������������������������ !"#�������e��� 2002� 8��� 2003� 8�f9�O�����Tgh/_) 37�8K�934i@�J�T,j_) 35���\�� �����klmnop�q��r�$�ghs' ��lmTtu#��� � vwL��xyz�,-)�� $%��������&�'()��������e�� �' �� 35���\��
!� �"� �{� |#� }$�r� %&~�� ������#���#����x�����'�)�#�� �'�W)-�� ���;����=(R���)#*+�,-)� EF��,�W)-�� �-���� ��.)�
* +
� IFN ����������,-�./�'()IFN �����e��(��1�������*+�,-)� 30�i@��u�_)�����/0�/���67��� �10�e�0�50��� 38�Ci@��!�33��� 9W�� D�V� }$�r��"� ��_� r�2�� �3��D�V�T�u�_)�� IFN-����������������,-�./�'()IFN-����������e��(��2���
,-)����yzEF� Table 1 ��H� � "¡����T 50�i@�� ��u�_)�@¢�����|#�45�6����_9 80�i@���_� �7�£~� ¤¥¦£~� §¨¦£~� ©ª£~'«¬#£~T8�vw�)������ �®39¯°±�²��G��� 9W-)15�� f)� ³��:;s 65.6�9.3 kg� :;´<L 60.8�9.7 kg9W-)��(�9 �D�V� �JU�W-)���'D�
Figure 1. An interview form for patients receiving IFN
monotherapy.
=µ¶· ¸¹º»�¼ �462
46
����� �Table 2� ���� ��� ��������������������� 50�� 34��23�� 23������ �� �������������� ���������������!"#$���%&��' (�� �Table 3� )*+� ,�"#$(-.&/�0'1���� �234-.�56�+78�9:���;<=> � � � ?@4 8ABC) 4A�)�DE'1;������� �FG�H�IJ���14 �Table 4����0:�
KL�0M1 4N� 1BO�FG�� -.P8QMIJ�R�=�8ST1� � U1�%V���1-.P8QMIJ�R�=�8WT FG4 35X
Y 12X�34��)*> �=�� Z[\]�^> 35X4� _`�abc
d%e_�^> fX4*> (��� UX� 24A/�-.�gh' �� ���������� �!"#�1� ijk�-.l 12A�)m��+"#$)*+� 35
XY 22X�m��� no 15X�p_cqjrs`�t$u� � FGvw�ij���%&cx��yM1qj`t$�%/�z�+9n�{|}~���+78� 0�H4���Y�ji'=�9n�� ��%/���'1���%/�z�+=,��y�^> ��2� ��
Figure 2. An interview form for patients receiving IFN-ribavirin com-
bination therapy
��������-.8��� 463
47
������� 20���� ���� ��������������� ��������28� 13��!�"����#$%&� '�() 12� �*+,�&��3� �-����*��.�/0����1�$%&15����� � 7 ��0�23�456� 35 � 22�������&� 078�9: ;<=�/16 ��>?@ABC"�D��E�F@GHIJ�D���*#K�� 20�078*LM�&��4� N�6��0���%/O�� PQ�RS�4T�*
U RSV��� ��WX���=%/4Y�$�8� � ��*ZK�[\U/� ]=�^��/_`�/V�aba��6&� �&� �� �9c=�/� defg�h6�iU ]=� �j��U ]=��k�&� N��l�����9�/4m�n0o��pq $Q�/9r�&��5� s� ts� t�9�/4� u�v!$s"���&swx�#%&�
�6� #$yz#aoyz*��&;e@4� ��{������� 3�*|}~��=$�� %"���*#K�&� ����&��'���]=�b�� ��������: ]=*v!�%&��7� IC�GC�35 � 1 ����&� ���(��'������������&� %"����=�U�����=������()� ���������&� IC�GC�4��Z)n����/�&��8� '��� 3�����b�� ��*�� +�&8�
� .��U&��V�&� �,=�a�&�����4� ���V_��+�����/���*�� �� ��V������-K�&�$�=+�2�/��a� ]����4� .��/*Vv!$]=� �0�$�ba�(�� ]�� 41+=1/*�¡2���*�=�&� �&� ����f¢£e¤�36�: ]=¥B¦§;e¨©C�nª�«4: ]=�U*+,�&�
� �
IFN ���4¬������5a]=*��/O�� ��* IFN ����q 0Qa0�®6 ¯�6a°±=$ 8�9�� IFN ���#K$0%&RS� Cj²³���0�478 5�7��´S�µ: � �&� ²³��5K$� C j9X²¶
Table 2. Frequency of Side E#ects in Patients Receiving
IFN-ribavirin Combination Therapy �2�Table 1. Frequency of Side E#ects in Patients Receiving
IFN-Ribavirin Combination Therapy �1�
:·¸¹ º»;f¼¥ �464
48
���������16�� � � IFN ����������� �������������������� �������� !"#�����$%&'�� ()� ����)*���+,&-�����.�� /������0"����� IFN12���345�67� �8�9�:;�<=>�?�.��@>���� @������:����ABCD�EF�G�HI�����J@>�� KL���MNOPQRSN���TUABCD�EF�G�HI��V@>���11�14��� WX����V�� Y��Z[5\)]^_*�>��� ��:�ABCD�EF�G� )>������`a� @������b�����c��V�'^17�� U5)de���Z[�f����gh�>��ijklNmnopqrstuv�wxXo&
�� IFN ��yz�{��� (#L�&n|�}
������ ~*)���<=>� MNQ�P����N�N��\�>)�zs���� IFN ��yz�� 2���zs��:�� ��MjkP��|�}������R��� ����d���l� �8|�}����y�<�=>�s����L��0���� � 3����� 2�4�������<=>�� 2�������<=>�������� ��|�������� �n|�������� �� 6¡&'�� � ����¢ABCD�EF�G�HI�£��¤¥7)*��� n|�¦h� ��|��§�p-��5�5���L����� ��¢Z¨�©=��ª«¬ �5(U)*� ��ª®��h���¯°¢�±�� n��²���³h�7�´µ� ��ª®�U(7�¶&-��´µ�'��gh�>�� U5)�±�·¸ �¹�5)��º����»��¼&'��
Table 3. Frequency of Serial Change of Side E#ects in Patients Receiv-
ing IFN-Ribavirin Combination Therapy
Table 4. Frequency of Patients with Damaged Daily Life
MNOPQRSN�����» 465
49
��������������� IFN �������� ������������� �� ����������������� ������ �����! �"#� ���$%�&�����������&��� '�(�) 11(��*�+� ��,�- .��'�)/012����3���������� 4������� 56���2���78���9�:#� �����; < =�����>?1��@AB@C��!�� .#2�D �E�F������ IFN ��� "G#2H#$�%$)I�4��&JK12��8�9�� 4������1�'�1�LE�)� '�()�M*N#2+O#� ,��������#�� 0�� �����2�+4����2)�������,�- PQ����R-���4��?��2��� 4���� �,�- .��(��.�O��� S�TU� 3*� 1��,�- PQ���#2��4��/0#��������#�4��V��#2� W�X�6��+����12���� =�2��YZ�[=4���3\�]�^�� P[��4��_4 ���4���`�1�� -�X56ab�7�� 608�c9�� �d:��+�6eR�>�5� ���+���� f<� �34)g+����� ;�h���7�2)i<���=j#2)����� ���8���� �7��� k* ��>�� �?K�]���� W���i<l@b�A0��YZ�BC#�� fD]���m Fn���?�>��>+4��op0�������4��_4����� 0�� qCrsCt�7��E9�� ��� =�2�FG�uv����� wH��+#2#0��S�I��x6:#�� 9 .��3\�Jn�yK�Lz ��?�uM�4� )��?�{� W� � �:# +�3\���� 4� �#2�N|O ��>+�} W� ~&P���4���������4��_4 ����@AB@C��!�������� ��� 5����^��6� �K ���Q��E��)� 181- 14-�7.7������^K12��16�� ���R#� 35-��� 1-�ST-):2���� ����R�*U-���R������
���� k*Fn���2����4��������2�+�V�[���2)��4�� K� ����ST���U����4��_4���4����#2���@AB@C��!�� .#2�� WCX� 8
����Y��Z[K11X� Y���X#2)�\]�^�#��4��/0#2��18�� ������a- .#2�_`��r���\��������4�)���>?1� Y���X .#2)W��Y����#������R��aM)����K�R� IFN ����p��fDN|�D�#2���)����� IFN ��� ��b� qC���C�ab�c�#�d������:������ fDN|ph����+� �|�����/���R�aM���� S4�@e�����:�f|Fgh����#2i�� 2003j 7�����#2�� �Figure 3�� D� �����w¡¢=�£���¤��¥k#� �����"�¦C�§���w�&��¨;� �� ©6lª��+4���m�#2��� 0�� K�R��n«��O������¬���?�������� ����#$ .#2�X�=����� �p���$ ����!® �¬#� �R�O��aM����2003j 12��� PEG-IFN a-2a ���19��o
¯����6� ° 1��p±���4�� ����%$�²�4����³q�{�´ª²�K1�� 0��p���WCK12��µ¶ IFN �@AB@C�!���K� S�VU�;rK1�
Figure 3. A communication form connecting hospital
ward and outpatient clinic.
K·¸¹ º»s¼@¦ �466
50
C������ IFN ���� ��� ���� �� ������������ �!"#$�%�&� '()*+)�,- ���./�0�� 1234 �5678��&9:#0;�1<� 12�56#=�&>? �@A�$� BCDE�FGHIJ� ���KL&0�;��*M��
� �
1� NOPQ� RSTQ� UVW� XYTQ� Z[\]� ��^_`abc�de� fg+ 2004;30: 1579�1584
2� Matsumura H, Moriyama M, Goto I, TanakaN, Okubo H, Arakawa Y. Natural course of
progression of liver fibrosis in Japanese pa-
tients with chronic liver disease type C-a study
of 527 patients at one establishment. J Viral
Hepat 2000; 7: 268�275.3� Yoshida H, Shiratori Y, Moriyama M,
Arakawa Y, Ide T, Sata M, Inoue O, Yano M,
Tanaka M, Fujiyama S, Nishiguchi S, Kuroki
T, Imazeki F, Yokosuka O, Kinoyama S, Ya-
mada G, Omata M, for the IHIT Study Group.
Interferon therapy reduces the risk for hepato-
cellular carcinoma: national surveillance pro-
gram of cirrhotic and noncirrhotic patients
with chronic hepatitis C in Japan. Ann Intern
Med 131; 1999; 131: 174�1814� Imai Y, Kawata S, Tamura S, Yabuuchi I,Noda S, Inada M, Maeda M, MD, Shirai Y,
Fukuzaki T, Kaji I, Ishikawa H, Matsuda Y,
Nishikawa M, Seki K, Matsuzawa Y. Relation
of Interferon Therapy and Hepatocellular Car-
cinoma in Patients with Chronic Hepatitis C.
Ann Intern Med 1998; 129: 94�995� Yoshida H, Arakawa Y, Sata M, Nishiguchi S,Yano M, Fujiyama S, Yamada G, Shiratori Y,
Omata M. Interferon therapy prolonged life
expectancy among chronic hepatitis C patients.
Gastroenterology 2002; 123: 483�4916� McHutchison JG, Gordon SC, Schi# ER,Shi#manML, LeeWM, Rustgi VK, Goodman
ZD, Ling MH, Cort S, Albrecht JK. Interferon
alfa-2b alone or in combination with ribavirin
as initial treatment for chronic hepatitis C.
Hepatitis Interventional Therapy Group. N
Engl J Med 1998; 339: 1485�927� Davis GL, Esteban-Mur R, Rustgi V, Hoefs J,Gordon SC, Trepo C, Shi#man ML, Zeuzem
S, Craxi A, Ling MH, Albrecht J. Interferon
alfa-2b alone or in combination with ribavirin
for the treatment of relapse of chronic hepatitis
C. International Hepatitis Interventional Ther-
apy Group. N Engl J Med 1998; 339: 1493�988� hijk: _lmnopql �IFN�r3:*8�st� �uv 1990; 21: 899�904
9� hijk: C������: '(wx 2001; 47:27�32
10� yYz{� |�}~�� ?z��� �� _lmnopql��S&�A���C��&���������57�9:� ��*a��n�l�� �C+e 1998; 40: 717�721
11� Hunt CM, Dominitz JA, Bute BP, Waters B,Blasi U, Williams DM. E#ect of Interferon-a
Treatment of Chronic Hepatitis C on Health-
Related Quality of Life. Dig Dis Sci 1997; 42:
2482�248612� Ahern M, Imperial J, Lam S. Impact of adesignated hepatology nurse on the clinical
course and quality of life of patients treated
with rebetron therapy for chronic hepatitis C.
Gastroenterol Nurs. 2004; 27: 149�5513� Ware JE, Bayliss MS, Mannocchia M, Davis
GL, and the international hepatitis interven-
tional therapy group.
14� Health-Related Quality of Life in Chronic
Hepatitis C: Impact of Disease and Treatment
Response. Hepatology 1999; 30: 550�555.15� Perrillo R, Rothstein KD, Rubin R, Alam I,Imperial J, Harb G, Hu S, Klaskala W. Com-
parison of quality of life, work productivity
and medical resource utilization of peginter-
feron alpha 2a vs the combination of interferon
alpha 2b plus ribavirin as initial treatment in
patients with chronic hepatitis C. J Viral Hepat
2004; 11: 157�16516� hijk� ���� XR��� �[��� ��� � ¡¢£¤� ¥¦§� |R¨§� ¡©ª
_lmnopql��*567 467
51
�� ��� Genotype 1b������� C ���������������� a-2b �SCH 18908 �������� !"#��������� a-2b $%"#��&'�()*+,-&'./!01!.�!��+2�3456 2002; 18: 565�591
17� Matsumura H, Moriyama M, Goto I, TanakaN, Okubo H, Arakawa Y. Natural course of
progression of liver fibrosis in Japanese pa-
tients with chronic liver disease type C�a studyof 527 patients at one establishment. J Viral
Hepat 2000; 7: 268�75.18� Bernstein D, Kleinman L, Barker CM, Revicki
DA, Green J. Relationship of Health-Related
Quality of Life to Treatment Adherence and
Sustained Response in Chronic Hepatitis C Pa-
tients. Hepatology 2002; 35: 704�708.19� Mchutchison JG, Manns M, Patel K, PoynardT, Lindsay KL, Trepo C, Dienstag J, Lee WM,
Mak C, Garaud JJ, Albrecht JK, for the inter-
national hepatitis interventional therapy
group. Adherence to combination therapy en-
hances sustained response in genotype-1 in-
fected patients with chronic hepatitis C. Gas-
troenterology 2002; 123: 1061�106920� Zeuzem S, Feinman SV, Rasenack J, Heath-cote EJ, Lai MY, Gane E, O[Grady J, Reichen
J, Diago M, Lin A, Ho#man J, Brunda MJ.
Peginterferon alfa-2a in patients with chronic
hepatitis C. N Engl J Med 2000; 343: 1666�1672
789: ;<=>�? @468
52
Abstract
A Study on the Side E#ects of Interferon Treatment Using a
Questionnaire for Patients with Chronic Hepatitis C
Noriko Motodate1, Mariko Akutsu1, Seiko Suzuki1, Kimie Yoshikawa1,
Yasuko Jinta1, Hiroshi Yotsuyanagi2, Michihiro Suzuki2,and Fumio Itoh2
An interview form was introduced for study of side e#ects, daily life� and work of patients withchronic hepatitis C who received interferon �IFN� treatment. The first interview form, introduced in June2001, was revised in December 2001. After that, side e#ects, daily life and work of the patients treated by
IFN-ribavirin combination therapy were analyzed. All the patients had some side e#ects. Common side
e#ects were skin itching followed by alopecia and edema. The frequency of each side e#ect is higher than that
on phase-III clinical trial, showing that the interview form can pick up side e#ects more accurately. Daily life
and work were damaged in one-third of the patients. However, no patient stopped treatment due to side
e#ects. Our experience shows the usefulness of interview form for intensive care and safe treatment.
Key words
Chronic hepatitis C, Interferon, Ribavirin, Questionnaire
1 Department of Nursing
2 Department of Internal Medicine, Division of Gastroenterogy and Hepatology, St. Marianna University.
����������� 469
53